Share-based Payment Arrangement, Expense of CG Oncology, Inc. from 31 Mar 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CG Oncology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2023 to 31 Dec 2025.
  • CG Oncology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $7,187,000, a 44% increase year-over-year.
  • CG Oncology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $26,676,000, a 134% increase year-over-year.
  • CG Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $26,676,000, a 134% increase from 2024.
  • CG Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,402,000, a 646% increase from 2023.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CG Oncology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $26,676,000 $7,187,000 +$2,197,000 +44% 01 Oct 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q3 2025 $24,479,000 $7,331,000 +$4,682,000 +177% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $19,797,000 $7,007,000 +$4,761,000 +212% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $15,036,000 $5,151,000 +$3,634,000 +240% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $11,402,000 $4,990,000 +$4,212,000 +541% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 $7,190,000 $2,649,000 +$2,255,000 +572% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $4,935,000 $2,246,000 +$2,069,000 +1169% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $2,866,000 $1,517,000 +$1,338,000 +747% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,528,000 $778,000 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
Q3 2023 $394,000 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $177,000 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $179,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1

CG Oncology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $26,676,000 +$15,274,000 +134% 01 Jan 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
2024 $11,402,000 +$9,874,000 +646% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
2023 $1,528,000 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.